Literature DB >> 21526496

Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sE-selectin levels in patients with type 1 diabetes complicated by microangiopathy.

Anna Kuryliszyn-Moskal1, Artur Dubicki, Wiesław Zarzycki, Anna Zonnenberg, Maria Górska.   

Abstract

Microvascular abnormalities are one of the most important causes of persistent diabetic complications. The aim of this study was to compare microvascular changes examined by nailfold capillaroscopy with serum concentrations of soluble E-selectin (sE-selectin) and IL-18 in type 1 diabetic patients with and without microangiopathy. Serum levels of sE-selectin and IL-18 were determined by an enzyme-linked immunosorbent assay in 106 patients with type 1 diabetes and in 40 healthy controls. All diabetic patients were evaluated by extensive clinical, laboratory and capillaroscopic studies. Morphological changes were observed by nailfold capillaroscopy in 86 out of 106 (81%) diabetic patients. Severe capillaroscopic changes were seen in 32 out of 54 (59%) patients with microangiopathy, but in only seven out of 52 (13%) patients without microangiopathy. Higher serum levels of sE-selectin (p < 0.001) and IL-18 (p < 0.05) were demonstrated in diabetic patients compared to controls. Significant differences of sE-selectin (p , 0.001) and IL-18 (p < 0.01) serum concentrations were observed between diabetic patients with microangiopathy and controls. Moreover, comparison between patients with and without microangiopathic complications showed a significantly higher capillaroscopic score and sE-selectin serum concentration in the group with microangiopathy (p < 0.001). Furthermore, diabetic patients with severe microvascular changes in capillaroscopy showed significantly higher IL-18 (p < 0.001) and sE-selectin (p < 0.05) serum levels than subgroups without changes or with mild abnormalities. Our findings suggest that abnormalities in nailfold capillaroscopy may reflect the extent of microvascular involvement and are associated with higher sE-selectin and IL-18 serum levels, as well as with microangiopathic complications in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21526496     DOI: 10.5603/fhc.2011.0015

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  5 in total

1.  Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome.

Authors:  Joanna Latuskiewicz-Potemska; Antonina Chmura-Skirlinska; Ryszard J Gurbiel; Elzbieta Smolewska
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

Review 2.  IL-18 in inflammatory and autoimmune disease.

Authors:  Saikiran K Sedimbi; Thomas Hägglöf; Mikael C I Karlsson
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

3.  Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance.

Authors:  Meriem Khairoun; Mieke van den Heuvel; Bernard M van den Berg; Oana Sorop; Rients de Boer; Nienke S van Ditzhuijzen; Ingeborg M Bajema; Hans J Baelde; Malu Zandbergen; Dirk J Duncker; Ton J Rabelink; Marlies E J Reinders; Wim J van der Giessen; Joris I Rotmans
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

4.  Skin oxygenation impairment is associated with increased total cholesterol level in children with short-lasting type 1 diabetes mellitus.

Authors:  Jolanta Neubauer-Geryk; Melanie Wielicka; Grzegorz M Kozera; Agnieszka Brandt-Varma; Anna Wołoszyn-Durkiewicz; Małgorzata Myśliwiec; Leszek Bieniaszewski
Journal:  Postepy Dermatol Alergol       Date:  2021-09-17       Impact factor: 1.837

5.  Decreased reactivity of skin microcirculation in response to L-arginine in later-onset type 1 diabetes.

Authors:  Jolanta Neubauer-Geryk; Grzegorz M Kozera; Bogumil Wolnik; Sebastian Szczyrba; Walenty M Nyka; Leszek Bieniaszewski
Journal:  Diabetes Care       Date:  2012-11-12       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.